Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Magle Chemoswed

Related articles:
4/19/2024 6:49:40 AM - Magle Chemoswed Q1: Expansion by acquisition - Redeye - Redeye provides a research update following the Q1 report recently published by Magle. The first quarter of 2024 for Magle was primarily marked by the public offer to acquire Amniotics. We believe that Amniotics' cGMP-licensed facilities will be able to generate long-term added value for Magle. Beyond that, the company reported a lower sales figure than expected at SEK38.2m, a -1% y/y decrease, with reduced revenue from its DSM products. However, we reiterate our previous fair value range (SEK25 – SEK58) with a base case valuation of SEK40.
4/18/2024 7:27:01 AM - Magle Chemoswed Q1: Initial take - Redeye - Redeye leaves an initial comment following the Q1 report published by Magle this morning. The first quarter of 2024 for Magle was primarily marked by the exciting public offer to acquire Amniotics. We believe that Amniotics' cGMP-licensed facilities for the development and manufacturing of advanced medicinal therapies will generate added value for Magle. Beyond that, the company reported a lower sales figure than expected, a -1% y/y decrease, with a reduced revenue from its DSM products. As OPEX and COGS were slightly above our expectations, this resulted in a lower EBIT and net cash flow than expected.
3/25/2024 6:23:32 AM - Magle Chemoswed: Public offer to acquire Amniotics - Redeye - Redeye leaves a comment following the Magle Group’s announced public offer to acquire Amniotics earlier today.
3/22/2024 6:38:49 AM - Magle Chemoswed lägger bud på Amniotics till 25 procents premie - Analysbolaget Magle Chemoswed lägger ett rekommenderat erbjudande på Amniotics värt cirka 10,9 miljoner kronor, enligt ett pressmeddelande.
2/16/2024 8:27:46 AM - Magle Chemoswed Q4: Initial take - Redeye - Redeye leaves an initial comment following the Q4 report published by Magle this morning. The company reported a higher sales figure than expected, a 25% y/y growth, bolstered by increased revenue from its DSM products. While OPEX and COGS were slightly above our expectations, this still resulted in a higher EBIT than expected. Overall, we are encouraged by the company’s Q4 report.
10/26/2023 7:49:36 AM - Magle Chemoswed Q3 2023: DSM business advancements - Redeye - Redeye leaves a comment on the Q3 report published by Magle yesterday. Overall, the report was in line with our expectations. While net sales came in slightly below our expectations due to a slower quarter for the contract manufacturing business, we are encouraged by the continuously growing sales from the DSM segment. We reiterate our previous fair value range (SEK25 – SEK58) with a base case valuation of SEK40 as we continue to have a positive outlook on the case.
10/25/2023 7:22:30 AM - Magle Chemoswed Q3: Initial take - Redeye - Redeye leaves an initial comment following the Q3 report published by Magle this morning. The company reported a y/y sales growth, but slightly below our net sales estimates. While OPEX and COGS were in line with our expectations, this resulted in a lower EBIT than expected. However, despite this, we do not expect to make any major adjustments to our long-term forecasts.
7/18/2023 7:26:48 AM - Magle Chemoswed Q2: Initial take - Redeye - Redeye leaves an initial comment following the Q2 report published by Magle this morning. Despite net sales being slightly lower than our estimates, the company effectively controlled its cash burn and reported an EBIT that surpassed our expectations. Overall, the Q2 report aligns well with what we anticipated, and any necessary adjustments to our long-term forecasts are expected to be minor.
5/10/2023 5:42:29 AM - Magle Chemoswed: The one-stop shop - Redeye - Redeye initiates coverage of Magle Chemoswed, a hybrid medtech/biotech company with a diverse array of revenue streams. Building on the foundations of its robust CDMO business, Magle is on the brink of commercial take-off with its portfolio of innovative medtech products. With its proprietary DSM technology platform as the focal point for the business, we see an ample growth story in the making with limited downside risk.
11/21/2022 8:41:18 AM - Magle Chemosweds sårgel godkänns i Kuwait - Magle Chemosweds sårgel har godkänts i Kuwait, enligt ett pressmeddelande.
11/14/2022 7:37:24 AM - Magle Chemoswed: Targeting profitability - VH Corp - * Net sales in Q3 fell short of our estimates<br>* High margin business areas continue to thrive<br>* We maintain our valuation interval SEK 46.60 – 62.80 SEK per share
8/19/2022 9:22:46 AM - Magle Chemoswed: Delivering healthy sales - VH Corp - * Strong net sales in Q2 due to high CDMO sales and royalties<br>* Impressive margins mean two out of three financial targets are met<br>* We maintain our valuation interval SEK 46.60 – 62.80 SEK per share
5/12/2022 1:00:52 PM - Magle Chemoswed: Strong margins due to mix - VH Corp - * Net sales in Q1 fell short of our estimates as manufacturing dipped<br>* Profits still outperformed due to beneficial sales mix<br>* We maintain our valuation interval SEK 46.60 – 62.80 SEK per share<br>Magle Chemoswed’s Q1 sales came in clearly below our estimates as sales of<br>generic APIs and contract manufacturing had an unusually weak quarter.<br>Operating margins and net profit came in impressively strong, however, due to<br>a shift towards high-margin business areas such as DSM sales and royalties, as<br>well as solid cost control. After the release of the Q1 report came news that<br>Magle Chemoswed has entered a pre-agreement to buy land next to its<br>productions site in Malmö, which enables future expansion of its CDMO<br>operations.
3/4/2022 10:19:43 AM - Magle Chemoswed: Resilience amid royalty dip - VH Corp - * Revenues in Q4 missed our estimate due to lagging royalty income<br>* Other business areas compensated, yielding a more diversified sales mix<br>* We maintain our valuation interval of SEK 46.60 – 62.80 per share
11/19/2021 11:58:32 AM - Magle Chemoswed: DSM products taking shape - VH Corp - * Revenue grew 12 percent and EBIT 81 percent in Q3
6/22/2020 11:16:19 AM - Magle Chemosweds notering övertecknad, inleder handel 30 juni - Magle Chemosweds notering övertecknad, inleder handel 30 juni
6/2/2020 1:12:26 PM - Magle Chemoswed ansöker om notering på First North - Magle Chemoswed ansöker om notering på First North